



GLP-1 RAs UNLOCKED

Transforming T2D Care from Pathology to Practice

Are you familiar with the current and emerging GLP-1 receptor agonist (RA) therapies and their multifaceted benefits?

CASE CHALLENGE

A 45-year-old man with a history of type 2 diabetes (T2D), hypertension, obesity, and established coronary artery disease presents to his rural primary care clinic for post-hospital follow-up. He was recently discharged from a tertiary care center following hospitalization for an acute coronary event, during which he underwent percutaneous coronary intervention with stent placement to his left anterior descending artery.

He is now back in his rural community and presenting for transition of care and optimization of his chronic disease management. His discharge medications include atorvastatin 80 mg daily, aspirin 81 mg daily, clopidogrel 75 mg daily, metformin 1000 mg BID, lisinopril 20 mg daily, and metoprolol succinate 50 mg daily.


Recent labs and findings:

- HbA1c: 8.2%
- eGFR: 62 mL/min/1.73 m²
- BMI: 34 kg/m²
- Blood pressure: 142/88 mmHg
- LDL-C: 58 mg/dL
- Urine albumin-creatinine ratio (uACR): 120 mg/g

BID = twice daily; eGFR = estimated glomerular filtration rate; BMI = body mass index; LDL-C = low-density lipoprotein cholesterol.

What systemic effects of GLP-1 RAs would help this patient? How would you decide which GLP-1 RA to prescribe? How would you dose it?

Summary of Key Physiologic Actions of GLP-1



GI = gastrointestinal; *GLP-1 actions on liver and muscle are indirect. Drucker DJ. *Cell Metab.* 2006;3:153-165.

FDA-Approved GLP-1 RA and GLP-1 RA/GIP Therapies

Generic Name	FDA-Approved Indications	Starting Dose	Titration Schedule Up-titration should be based on patient tolerance and clinical goals. Maximum doses listed are not target doses, unless specified.
Dulaglutide SC weekly	T2D in patients ≥ 10 years of age MACE reduction in adults with T2D with CVD or multiple CVD risk factors	0.75 mg weekly x 4 weeks	1.5 mg weekly x 4 weeks (dose studied in CVD) 3 mg weekly x 4 weeks 4.5 mg weekly (maximum dosage) Maintenance doses: 1.5 mg – 4 mg
Exenatide SC BID	T2D in adults	5 mcg BID x 4 weeks Take doses within 1 hour before a meal (at least 6 hours apart)	10 mcg twice daily (recommended dose, maximum dose)
Exenatide SC weekly		2 mg weekly	N/A
Liraglutide SC daily	T2D in patients ≥ 10 years of age MACE reduction in patients with T2D and established CVD	0.6 mg daily, week 1	1.2 mg daily, week 2 1.8 mg daily (maximum dose, dose studied in CVD) Maintenance doses: 1.2 mg or 1.8 mg based on tolerance and glycemic control
	Weight reduction and maintenance in patients ≥ 12 years of age with body weight > 60 kg and obesity Adults with overweight in the presence of at least one weight-related comorbidity	0.6 mg daily, week 1 Any time of day without regard for meals	1.2 mg daily, week 2 1.8 mg daily, week 3 2.4 mg daily, week 4 3.0 mg (target dose, lower doses are for titration only)
Semaglutide SC weekly	T2D MACE reduction in patients with T2D and established CVD Reduce risk of eGFR decline, ESRD, and CV-related death in adults with T2D and CKD	0.25 mg x 1 week 1	0.5 mg x 1 week 2 1 mg x 1 week 3 2 mg x 1 weekly (maximum dose) Maintenance doses: T2D, MACE risk reduction: 0.5 mg, 1 mg, or 2 mg, based on tolerance and glycemic control (0.5 mg and 1 mg were studied in CVD) CKD: 1 mg weekly
	Weight reduction and maintenance in patients ≥ 12 years of age with obesity Adults with overweight in the presence of at least one weight-related comorbidity MACE reduction in patients with established CVD and either obesity or overweight Treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults	0.25 mg weekly x 4 weeks	0.5 x 4 weeks 1 mg x 4 weeks 1.7 mg x 4 weeks 2.4 mg (maximum dose) Maintenance doses: 2.4 mg (recommended) or 1.7 mg based on tolerance 2.4 mg (studied in CVD and MASH)

Generic Name	FDA-Approved Indications	Starting Dose	Titration Schedule Up-titration should be based on patient tolerance and clinical goals. Maximum doses listed are not target doses, unless specified.
Semaglutide Oral daily	T2D	3 mg daily × 30 days	7 mg × 30 days 14 mg (maximum dose) Maintenance doses 7 mg or 14 mg based on tolerance and glycemic control
Tirzepatide SC weekly	T2D	2.5 mg weekly × 4 weeks	5 mg weekly × 4 weeks 7.5 mg weekly × 4 weeks 10 mg weekly × 4 weeks 12.5 mg weekly × 4 weeks 15 mg weekly (maximum dose)
	Adults with obesity in the presence of at least one weight-related comorbidity OSA in adults with obesity	2.5 mg weekly × 4 weeks	Maintenance doses T2D: 5 mg-15 mg based on tolerance and glycemic control Obesity: 5 mg-15 mg based on tolerance OSA: 10 mg and 15 mg doses

CVD = cardiovascular disease; CKD = chronic kidney disease; MACE = major adverse cardiovascular events; ESRD = end-stage renal disease; OSA = obstructive sleep apnea, SC = subcutaneous; CKM = cardiovascular-kidney-metabolic; MASH = metabolic dysfunction-associated steatohepatitis.

WHY THIS MATTERS

- Knowing when a GLP-1 RA should be considered in patients with significant multimorbidity can improve outcomes
- Knowing how to select the correct dose and titration schedule can help decrease side effects and increase adherence
- This program will aid clinicians by providing foundational education on the systemic effects of GLP-1 RAs as well as how to effectively assess if they will benefit complex patients

Watch CME Outfitters' 6-episode webcast series on CKM health and GLP-1 RAs to learn more! Complete all 6 activities and claim your badge as a Patient-First Diabetes Management Champion!

REFERENCES

1. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment. *Diabetes Care*. 2025;48(Suppl 1):S158-S178.
2. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2025;13(1):15-28.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. 2007;132(6):2131-2157.
4. Cho YK, La Lee Y, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. *J Lipid Atheroscler*. 2023;12(3):213-222.
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet*. 2006;368(9548):1696-1705.
6. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab*. 2018;27(4):740-756.
7. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab*. 2016;24(1):15-30.
8. Dulaglutide [package insert]. U.S. Food and Drug Administration Website. Revised 2025. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125469s063lbl.pdf.
9. Exenatide [package insert]. U.S. Food and Drug Administration Website. Revised 2025. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209210s025lbl.pdf.
10. Exenatide [package insert]. U.S. Food and Drug Administration Website. Revised 2009. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s1s18s22s25lbl.pdf.
11. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). *Lancet*. 2019;394(10193):121-130.
12. Kataoka Y, Kitahara S, Funabashi S, et al. Glucagon-like peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: the prespecified sub-analysis of the OPTIMAL randomized clinical trial. *Atheroscler Plus*. 2024;56:1-6.
13. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389:2221-2232.
14. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834-1844.
15. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.
16. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. *Am Heart J*. 2024;267:1-11.
17. Pahud de Mortanges A, Sinaci E, Salvador D Jr., et al. GLP-1 receptor agonists and coronary arteries: from mechanisms to events. *Front Pharmacol*. 2022;13:856111.
18. Perkovic V, Tuttle KR, Rossing P, et al. Semaglutide effects on chronic kidney disease in T2D (FLOW trial). *N Engl J Med*. 2024;391(2):109-121.
19. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in T2D. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662.

REFERENCES (CONT.)

20. Semaglutide [package insert]. U.S. Food and Drug Administration Website. Revised 2021. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf.
21. Semaglutide [package insert]. U.S. Food and Drug Administration Website. Revised 2017. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf.
22. Semaglutide [package insert]. U.S. Food and Drug Administration Website. Revised 2020. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf.
23. Tirzepatide [package insert]. U.S. Food and Drug Administration Website. Revised 2022. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf.
24. Tirzepatide [package insert]. U.S. Food and Drug Administration Website. Revised 2025. Accessed July 23, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf.
25. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in overweight or obese adults. *N Engl J Med*. 2021;384(11):989-1002.
26. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal Transduct Target Ther*. 2024;9:234.